707 related articles for article (PubMed ID: 14528301)
1. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
Marin M; Rose KM; Kozak SL; Kabat D
Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
[TBL] [Abstract][Full Text] [Related]
2. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
3. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
Mehle A; Strack B; Ancuta P; Zhang C; McPike M; Gabuzda D
J Biol Chem; 2004 Feb; 279(9):7792-8. PubMed ID: 14672928
[TBL] [Abstract][Full Text] [Related]
4. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Sheehy AM; Gaddis NC; Malim MH
Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
[TBL] [Abstract][Full Text] [Related]
5. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
Liu B; Yu X; Luo K; Yu Y; Yu XF
J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
[TBL] [Abstract][Full Text] [Related]
6. New insights into the role of Vif in HIV-1 replication.
Schröfelbauer B; Yu Q; Landau NR
AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K; de Noronha C; Yonemoto W; Greene WC
Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
[TBL] [Abstract][Full Text] [Related]
8. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
Schröfelbauer B; Chen D; Landau NR
Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3927-32. PubMed ID: 14978281
[TBL] [Abstract][Full Text] [Related]
9. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
Yu X; Yu Y; Liu B; Luo K; Kong W; Mao P; Yu XF
Science; 2003 Nov; 302(5647):1056-60. PubMed ID: 14564014
[TBL] [Abstract][Full Text] [Related]
10. Functional domains of APOBEC3G required for antiviral activity.
Li J; Potash MJ; Volsky DJ
J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
[TBL] [Abstract][Full Text] [Related]
11. The viral infectivity factor (Vif) of HIV-1 unveiled.
Rose KM; Marin M; Kozak SL; Kabat D
Trends Mol Med; 2004 Jun; 10(6):291-7. PubMed ID: 15177194
[TBL] [Abstract][Full Text] [Related]
12. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
Conticello SG; Harris RS; Neuberger MS
Curr Biol; 2003 Nov; 13(22):2009-13. PubMed ID: 14614829
[TBL] [Abstract][Full Text] [Related]
13. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.
Mehle A; Goncalves J; Santa-Marta M; McPike M; Gabuzda D
Genes Dev; 2004 Dec; 18(23):2861-6. PubMed ID: 15574592
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
[TBL] [Abstract][Full Text] [Related]
17. Rapid evolution of primate antiviral enzyme APOBEC3G.
Zhang J; Webb DM
Hum Mol Genet; 2004 Aug; 13(16):1785-91. PubMed ID: 15198990
[TBL] [Abstract][Full Text] [Related]
18. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
Goncalves J; Santa-Marta M
Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
[TBL] [Abstract][Full Text] [Related]
20. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]